The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo

[1]  M. Yohe,et al.  Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma , 2021, Genes.

[2]  S. Veuger,et al.  Reversing oncogenic transformation with iron chelation , 2021, Oncotarget.

[3]  N. Yamamoto,et al.  Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma , 2020, Cancers.

[4]  F. Sotgia,et al.  Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production , 2020, Cells.

[5]  P. Leedman,et al.  Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology , 2020, Frontiers in Oncology.

[6]  R. Saab,et al.  Signaling pathways in Rhabdomyosarcoma invasion and metastasis , 2020, Cancer and Metastasis Reviews.

[7]  S. Fulda,et al.  Targeting ferroptosis in rhabdomyosarcoma cells , 2020, International journal of cancer.

[8]  A. Ferrari,et al.  Rhabdomyosarcoma , 2019, Nature Reviews Disease Primers.

[9]  D. Girelli,et al.  Sucrosomial® Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation , 2018, Nutrients.

[10]  F. Torti,et al.  Iron and Cancer. , 2018, Annual review of nutrition.

[11]  M. Poli,et al.  Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines , 2018, Journal of Cancer Research and Clinical Oncology.

[12]  C. Camaschella,et al.  Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma , 2017, Leukemia.

[13]  M. Arnold,et al.  Molecular diagnostics in the management of rhabdomyosarcoma , 2017, Expert review of molecular diagnostics.

[14]  Morteza Mahmoudi,et al.  Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. , 2016, Nature nanotechnology.

[15]  Y. Tsuji,et al.  Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. , 2016, Trends in biochemical sciences.

[16]  S. Rivella,et al.  Cancer cells with irons in the fire. , 2013, Free radical biology & medicine.

[17]  James R. Anderson,et al.  PAX‐FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report , 2013, Pediatric blood & cancer.

[18]  G. Tonon,et al.  Iron increases the susceptibility of multiple myeloma cells to bortezomib , 2013, Haematologica.

[19]  F. Torti,et al.  Iron and cancer: more ore to be mined , 2013, Nature Reviews Cancer.

[20]  S. Kaal,et al.  Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: the road ahead. , 2012, Critical reviews in oncology/hematology.

[21]  S. Ognjanovic,et al.  Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005 , 2009, Cancer.

[22]  Angelo Rosolen,et al.  Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion , 2009, BMC Cancer.

[23]  K. Pantopoulos,et al.  Iron metabolism and toxicity. , 2005, Toxicology and applied pharmacology.

[24]  James R. Anderson,et al.  Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V , 2001, Journal of pediatric hematology/oncology.

[25]  博之 伊藤,et al.  急激に発生した篩骨洞 rhabdomyosarcoma 症例 , 1979 .